Kan chen

Partner at Qiming Venture Partners, Formal Senior Scientist at JNJ, Harvard trained immunologist, tweets completely my own

[Kan chen @chenkan8201]

@andrewpannu Sleuth

[Goose Data (wa/wa) @GooseData]

What even is.... Too crowded?

🤔

[Qiming Venture Partners @QimingVC]

Congrats to @Abbisko2016 for achieving a major milestone! Pimicotinib is an orally available, highly selective and potent small molecule inhibitor of CSF-1R, which received the BTD from China NMPA and FDA, along with the PRIME designation from the EMA.

[Qiming Venture Partners @QimingVC]

Medilink Therapeutics is set to showcase its next-generation #ADC technology platform TMALIN (Tumor Microenvironment Activatable LINker-payload), along with the latest preclinical data on the innovative ADC YL205, for the first time at #AACR 2024.

[Abbisko Therapeutics @Abbisko2016]

28 Feb. 2024, Abbisko presented the preliminary first-in-human results of its next-generation highly selective FGFR2/3 inhibitor ABSK061 in patients with advanced solid tumors during the 2024 European Society for Medical Oncology Targeted Anticancer Therapies Congress @myESMO.

[Qiming Venture Partners @QimingVC]

#QMPortfolio OriCell Therapeutics' IND application for OriCAR-017 has been granted by the US FDA. OriCAR-017 is an innovative CAR-T therapy targeting GPRC5D for patients with relapsed/refractory multiple myeloma. The company will gear up to launch clinical development in the US.

[Qiming Venture Partners @QimingVC]

An inspiring evening as we gathered with CEOs of our portfolio companies who attended #JPM24. Innovation in healthcare knows no borders. Qiming will continue to champion innovators who are setting new standards in healthcare and facilitate a worldwide reach. #QMhealthcare

[Qiming Venture Partners @QimingVC]

Exciting news from #QMportfolio Medilink Therapeutcis! They've reached a global collaboration and license agreement with @Roche for the development of its ADC candidate YL211 targeting c-Met against solid tumors.
https://t.co/By8sECZKES

[Biotech Investor @learnbiotech]

The most active (by # of deals) biopharma investors is an interesting list:

Many companies will tout RA Capital as a shareholder but remember they are in many deals
Alexandria take stakes when companies use their space
ARCH writes big checks so keep an eye on them

[Qiming Venture Partners @QimingVC]

Congrats to @Abbisko2016 (SEHK:2256) on the #partnership with @Merck! Dr. Xu Yao-chang, Chairman of Abbisko, sees it as a crucial milestone for the global commercialization of pimicotinib and a new model for the company's pipeline. #QMPortfolio #QMHealthcare

[Insilico Medicine @InSilicoMeds]

A new story in @Bloomberg captures Insilico's leading role in #AI drug discovery, as we continue to advance the first fully generative AI drug for #IPF through mid-stage trials with initial results expected early 2025.
@kanokomatsuyama https://t.co/bNQA7nagKv

[Kan chen @chenkan8201]

We are officially entering the era of gene editing!

[Julian Grünewald @grunewaju]

First approval for a #CRISPR therapy in the world. UK MHRA has authorized Exagamglogene autotemcel (Casgevy) this morning. What a historic and uplifting day for patients and for the gene & cell therapy field. https://t.co/n0NQxwbdRs

[Abbisko Therapeutics @Abbisko2016]

9 Nov 2023, Shanghai—Abbisko Therapeutics today announced that ABSK051, a novel small molecule CD73 inhibitor, has obtained the clinical trial approval from the National Medical Products Administration (NMPA) of the People’s Republic of China.
#bio #pharma #inhibitor #cancer

[Abbisko Therapeutics @Abbisko2016]

Abbisko Therapeutics Obtained Approval from U.S. FDA to Conduct First-in-Human (FIH) Clinical Study of A Next-Generation FGFR4 Mutant Inhibitor ABSK012

[Qiming Venture Partners @QimingVC]

We are excited to share that Qiming ranked No.5 among top global investors in the @VCJournal VCJ50 2023!

The annuaal VCJ 50 evaluates VC firms based on the amount of direct investment capital raised for seed, early, and multi-stage deals, excluding growth deals.
#QMawards

[Kan chen @chenkan8201]

Congrats to our portfolio company Insilico Medicine for their licensing agreement with Exelixis for ISM3091, a Potentially Best-in-Class USP1 Inhibitor - https://t.co/yd0iGItrh9

[Kan chen @chenkan8201]

Congrats to the IPO of our portfolio company Structure Tx!

https://t.co/3URREv2n5n

[Kan chen @chenkan8201]

😪😪😪

[Brad Loncar @bradloncar]

So far the weather outlook for #JPM23 is looking beautiful.

[Kan chen @chenkan8201]

Congrats to Belief BioMed!

[Qiming Venture Partners @QimingVC]

#QMPortfolio Belief BioMed announced that its self-developed and manufactured BBM-H803 injection was granted @US_FDA orphan drug designation for #hemophilia A, marking the 2nd gene therapy drug candidate with FDA ODD following BBM-H901 for hemophilia B.

https://t.co/EBNIxv3M29

[Kan chen @chenkan8201]

Will be back at JPM healthcare conference the coming Jan after three years. Look forward to reconnecting with old friends and meeting new ones! #JPM23